RGLS - レグルス・セラピュ―ティクス (Regulus Therapeutics Inc.)

RGLSのニュース

   Regulus Therapeutics Reports First Quarter 2020 Financial Results and Recent Updates  2020/05/14 20:07:00 PR Newswire
LA JOLLA, Calif., May 14, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first quarter…
   Regulus (RGLS) Expected to Beat Earnings Estimates: Should You Buy?  2020/05/07 16:30:46 Zacks Investment Research
Regulus (RGLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx  2020/01/10 12:13:12 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: AGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) ( announced positive midstage results for its gene therapy to treat inherited eye disorder) Applied Therapeutics Inc (NASDAQ: APLT ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) COLLPLANT BIOTE/S ADR (NASDAQ: CLGN ) DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ) (reported positive results for a late-stage study of its peanut allergy patch) DexCom, Inc. (NASDAQ: DXCM ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Inspire Medical Systems Inc (NYSE: INSP ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) LeMaitre Vascular Inc (NASDAQ: LMAT ) Masimo Corporation (NASDAQ: MASI ) Medtronic PLC (NYSE: MDT )(announced the acquisition of Stimgenics) Molecular Templates Inc (NASDAQ: MTEM ) Morphosys Ag (NASDAQ: MOR ) NuVasive, Inc.
   Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326  2019/12/16 13:00:00 PR Newswire
LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration ("FDA") has lifted the Partial…
   Regulus Therapeutics to Present at the Stifel Healthcare Conference  2019/11/18 13:07:00 Yahoo Finance
LA JOLLA, Calif., Nov. 18, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present a company
   The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx  2020/01/10 12:13:12 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: AGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) ( announced positive midstage results for its gene therapy to treat inherited eye disorder) Applied Therapeutics Inc (NASDAQ: APLT ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) COLLPLANT BIOTE/S ADR (NASDAQ: CLGN ) DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ) (reported positive results for a late-stage study of its peanut allergy patch) DexCom, Inc. (NASDAQ: DXCM ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Inspire Medical Systems Inc (NYSE: INSP ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) LeMaitre Vascular Inc (NASDAQ: LMAT ) Masimo Corporation (NASDAQ: MASI ) Medtronic PLC (NYSE: MDT )(announced the acquisition of Stimgenics) Molecular Templates Inc (NASDAQ: MTEM ) Morphosys Ag (NASDAQ: MOR ) NuVasive, Inc.
   Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326  2019/12/16 13:00:00 PR Newswire
LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration ("FDA") has lifted the Partial…
   Regulus Therapeutics to Present at the Stifel Healthcare Conference  2019/11/18 13:07:00 Yahoo Finance
LA JOLLA, Calif., Nov. 18, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present a company
   Regulus Therapeutics (NASDAQ:RGLS) Posts Quarterly Earnings Results, Hits Estimates  2019/11/14 05:04:40 Modern Readers
Regulus Therapeutics (NASDAQ:RGLS) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, meeting the consensus estimate of ($0.26), Fidelity Earnings reports. Regulus Therapeutics had a negative net margin of 396.84% and a negative return on equity of 179,717.33%. The business had revenue of $0.02 million during the […]
   Regulus Therapeutics Reports Third Quarter 2019 Financial Results and Recent Updates  2019/11/12 21:05:00 PR Newswire
LA JOLLA, Calif., Nov. 12, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the third quarter…
   Regulus to Present Preclinical Efficacy Data Highlighting Potential of Novel Treatment for Nonalcoholic Steatohepatitis at The International Liver Congress(TM) 2019  2019-04-08 PR Newswire
LA JOLLA, Calif. , April 8, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present preclinical data on the therapeutic pote…

calendar